Apr. 21 at 1:15 PM
$MDCX $LLY $GME $JNJ
Teverelix is estimated by its developer, Medicus Pharma, to be a combined
$6 billion annual market opportunity across its primary urological indications.
Market Opportunity Breakdown:
Prostate Cancer (
$4B+ Market): Targeted toward patients with high cardiovascular risk. Estimates indicate 300,000 to 500,000 men in the U.S. live with advanced prostate cancer, representing a potential
$4 billion annual opportunity.
Acute Urinary Retention (
$2B Market): Aimed at preventing recurrence (AURr) in men with enlarged prostates (BPH). This is positioned as a potential first-in-market pharmacologic therapy for this specific condition, valued at
$2 billion.
